Discussing axSpA: 52-week results from the Phase 3 BE MOBILE trials
Join Dr Sofia Ramiro and Dr Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered whether men and women with axSpA respond differently to bimekizumab, using 52-week data from the BE MOBILE 1 and 2 trials, covering both non-radiographic and radiographic axSpA.
You May Also Like
Shimon Davis
Shimon Davis
Typical Skeptic Podcast
Robert Kalil
Inside Islam
Inside Islam Podcast
Lana Blakely
Lana Blakely
Rick Warren Sermons
Word Life
MAX Health and Fitness Recordings
Max International College for Fitness Professionals
Каббала Медиа | mp3 #kab_rus
Bnei Baruch Kabbalah Education and Research Institute, Бней Барух – Ассоциация "Каббала Ла-Ам"
Chink Positive
Chinkee Tan and and The Pod Network Entertainment
Choses à Savoir - Culture générale
Choses à Savoir
Langsam Gesprochene Nachrichten | Audios | DW Deutsch lernen
DW
Shimon Davis
Shimon Davis
Typical Skeptic Podcast
Robert Kalil
Inside Islam
Inside Islam Podcast
Lana Blakely
Lana Blakely
Rick Warren Sermons
Word Life
MAX Health and Fitness Recordings
Max International College for Fitness Professionals
Каббала Медиа | mp3 #kab_rus
Bnei Baruch Kabbalah Education and Research Institute, Бней Барух – Ассоциация "Каббала Ла-Ам"
Chink Positive
Chinkee Tan and and The Pod Network Entertainment
Choses à Savoir - Culture générale
Choses à Savoir
Langsam Gesprochene Nachrichten | Audios | DW Deutsch lernen
DW
Community discussion